Cargando…

Machine-learning classification identifies patients with early systemic sclerosis as abatacept responders via CD28 pathway modulation

Here, the efficacy of abatacept in patients with early diffuse systemic sclerosis (dcSSc) was analyzed to test the hypothesis that patients in the inflammatory intrinsic subset would show the most significant clinical improvement. Eighty-four participants with dcSSc were randomized to receive abatac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mehta, Bhaven K., Espinoza, Monica E., Franks, Jennifer M., Yuan, Yiwei, Wang, Yue, Wood, Tammara, Gudjonsson, Johann E., Spino, Cathie, Fox, David A., Khanna, Dinesh, Whitfield, Michael L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869963/ https://www.ncbi.nlm.nih.gov/pubmed/36355434 http://dx.doi.org/10.1172/jci.insight.155282

Ejemplares similares

Microbiome dysbiosis is associated with disease duration and increased inflammatory gene expression in systemic sclerosis skin
por: Johnson, Michael E., et al.
Publicado: (2019)

Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis
por: Chakravarty, Eliza F., et al.
Publicado: (2015)

Randomized Clinical Trial Design to Assess Abatacept in Resistant Nephrotic Syndrome
por: Trachtman, Howard, et al.
Publicado: (2017)

Regulator combinations identify systemic sclerosis patients with more severe disease
por: Wang, Yue, et al.
Publicado: (2020)

Senescent Cells Accumulate in Systemic Sclerosis Skin
por: Shi, Bo, et al.
Publicado: (2023)

A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers
por: Nagaraja, Vivek, et al.
Publicado: (2019)

Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis
por: Fox, David A., et al.
Publicado: (2021)

Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial
por: Khanna, Dinesh, et al.
Publicado: (2022)

Correction to: Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis
por: Fox, David A., et al.
Publicado: (2021)

High Rhodotorula sequences in skin transcriptome of patients with diffuse systemic sclerosis
por: Arron, Sarah T., et al.
Publicado: (2014)

1,25(OH)(2)D(3) Promotes the Efficacy of CD28 Costimulation Blockade by Abatacept
por: Gardner, David H., et al.
Publicado: (2015)

Patient‐Reported Outcomes From a Two‐Year Head‐to‐Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis
por: Fleischmann, Roy, et al.
Publicado: (2016)

Systems Level Analysis of Systemic Sclerosis Shows a Network of Immune and Profibrotic Pathways Connected with Genetic Polymorphisms
por: Mahoney, J. Matthew, et al.
Publicado: (2015)

A Cost per Responder Model for Abatacept versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity
por: Park, Sang Hee, et al.
Publicado: (2020)

Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy
por: Caporali, Roberto, et al.
Publicado: (2022)

Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008)

Abatacept in the treatment of rheumatoid arthritis
por: Vital, Edward M, et al.
Publicado: (2006)

Abatacept treatment for rheumatoid arthritis
por: Schiff, Michael
Publicado: (2011)

Subcutaneous Abatacept vErsus Intravenous Abatacept: A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate
por: Genovese, M C, et al.
Publicado: (2011)

Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial
por: Gordon, Jessica K., et al.
Publicado: (2015)

Subcutaneous abatacept for the treatment of rheumatoid arthritis
por: Schiff, Michael
Publicado: (2013)

Experience with abatacept in refractory lupus nephritis
por: Calatayud, Emma, et al.
Publicado: (2023)

PReS-FINAL-2327: Abatacept in the treatment of refractory uveitis
por: Moretti, D, et al.
Publicado: (2013)

Costo per responder di upadacitinib e abatacept nel trattamento dell’artrite reumatoide da moderata a grave in Italia
por: Caporali, Roberto, et al.
Publicado: (2021)

Abatacept to treat chronic intestinal pseudo-obstruction in five systemic sclerosis patients with a description of the index case
por: Vigone, Barbara, et al.
Publicado: (2018)

Abatacept in difficult-to-treat juvenile idiopathic arthritis
por: Kuemmerle-Deschner, Jasmin B, et al.
Publicado: (2008)

Abatacept as a Therapeutic Option for Rheumatoid Vasculitis
por: Al Attar, Layth, et al.
Publicado: (2018)

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study
por: Schiff, Michael, et al.
Publicado: (2011)

A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis
por: Taroni, Jaclyn N., et al.
Publicado: (2017)

SNP algorithms for prediction of efficacy and adverse events of abatacept (ABT)
por: Middleton, James E, et al.
Publicado: (2012)

Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
por: Truchetet, Marie-Elise, et al.
Publicado: (2016)

Efficacy of abatacept in juvenile idiopathic arthritis related uveitis
por: Katargina, LA, et al.
Publicado: (2011)

Abatacept: the evidence for its place in the treatment of rheumatoid arthritis
por: Köller, Marcus D.
Publicado: (2007)

Abatacept in psoriatic arthritis: Case report and short review
por: Ursini, Francesco, et al.
Publicado: (2013)

Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis
por: Lutt, Joseph R
Publicado: (2009)

Current treatment options for psoriatic arthritis: spotlight on abatacept
por: Ursini, Francesco, et al.
Publicado: (2018)

The Use of Abatacept for the Treatment of Felty Syndrome in Rheumatoid Arthritis
por: Chin, Rishika V, et al.
Publicado: (2023)

Pneumocystis jirovecii Pneumonia in a Patient with Rheumatoid Arthritis Treated with Abatacept
por: Ospina, Fabio E., et al.
Publicado: (2014)

Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo‐Controlled Trial in Adults With Systemic Sclerosis
por: Spiera, Robert, et al.
Publicado: (2020)

Abatacept versus other biologics in methotrexate inadequate responders with rheumatoid arthritis: you like tomato and I like tomahto... let's call the whole thing off
por: Yazici, Yusuf
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_90lnt344mmv0mlf3u06227fq5j